FATE THERAPEUTICS INC Customer Breakdown
Customer relationships and concentrations across all retained periods. Named customers and their revenue are shown when disclosed. Anonymous customers, customer groups and sales channels are labelled separately. Receivable concentration measures unpaid balances, not revenue contribution. A biggest customer by revenue can be identified only from disclosed customer revenue. Missing names and amounts remain missing; identities are not assumed to match between periods.
| Period / as of | Customer / group | Category | Customer revenue | Share of revenue | Share of trade receivables | Basis and limitations |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
|---|
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
|---|